Leire Berrocal
A5070081054- HIV/AIDS drug development and treatment
- HIV Research and Treatment
- HIV/AIDS Research and Interventions
- HIV-related health complications and treatments
- COVID-19 Clinical Research Studies
- Pneumocystis jirovecii pneumonia detection and treatment
- COVID-19 Impact on Reproduction
- COVID-19 and healthcare impacts
- Hepatitis C virus research
- Liver Disease and Transplantation
- Rheumatoid Arthritis Research and Therapies
- HIV, Drug Use, Sexual Risk
- Pancreatitis Pathology and Treatment
- Renal Transplantation Outcomes and Treatments
- Patient-Provider Communication in Healthcare
- Osteomyelitis and Bone Disorders Research
- Liver Disease Diagnosis and Treatment
- Patient Satisfaction in Healthcare
- Spondyloarthritis Studies and Treatments
Universitat de Barcelona
2021-2025
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer
2021-2025
Hospital Clínic de Barcelona
2023-2024
Fundació de Recerca Clínic Barcelona-Institut d’Investigacions Biomèdiques August Pi i Sunyer
2023-2024
Fundació Clínic per a la Recerca Biomèdica
2023-2024
BackgroundFactors affecting outcomes of SARS-CoV-2 infection in people living with HIV are unclear. We assessed the factors associated diagnosis and severe among HIV.MethodsWe did a retrospective cohort study using data from PISCIS Catalonia (Spain) between March 1 Dec 15, 2020. linked integrated health-care, clinical, surveillance registries through Public Data Analysis for Health Research Innovation Program (PADRIS) to obtain on diagnosis, chronic comorbidities, as well clinical mortality...
The use of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) is mainly based on robust, pivotal clinical trials.To provide data BIC/FTC/TAF in real life.This was an observational, retrospective and single-centre study. We included all adult, treatment-naive (TN) treatment-experienced (TE) people living with HIV (PLWH) starting from 8 June 2018. evaluated effectiveness [on treatment (OT), modified intention-to-treat (mITT) (ITT)], tolerability safety those patients who reached 6...
Journal Article Cohort Profile: PISCIS, a population-based cohort of people living with HIV in Catalonia and Balearic Islands Get access Andreu Bruguera, Bruguera Centre Epidemiological Studies STI HIV/AIDS (CEEISCAT), Department Health, Generalitat de Catalunya, Badalona, SpainInstitute for Health Science Research Germans Trias i Pujol (IGTP), SpainCIBER Epidemiologia y Salud Pública (CIBERESP), Madrid, Spain https://orcid.org/0000-0002-7524-0768 Search other works by this author on: Oxford...
Abstract Background This study assessed the pharmacokinetic interactions between dolutegravir (DTG)-based antiretroviral therapy (ART) and immunosuppressants in solid organ transplantation (SOT) recipients with HIV ART safety. Methods A phase IV, single-center, open-label, single-arm clinical trial (DTG-SOT, NCT03360682) including adult SOT conducted 2017 2019. People plasma viral load <50 copies/mL during ≥12 months receiving stable raltegravir-based ≥6 were switched to tenofovir...
Reports on the impact of some antiretrovirals against SARS-CoV-2 infection and disease severity are conflicting.We evaluated effect tenofovir as either alafenamide/emtricitabine (TAF/FTC) or disoproxil fumarate/emtricitabine (TDF/FTC) associated clinical outcomes among people living with HIV (PLWH).We conducted a propensity score-matched analysis in prospective PISCIS cohort PLWH (n = 14 978) Catalonia, Spain. We used adjusted Cox regression models to assess association between...
Abstract Background The use of dolutegravir/lamivudine is based on solid clinical trials; however, real-world data remain limited. Objectives To provide the and effectiveness in persons with HIV a scenario. Patients methods Retrospective, single-centre observational study. We included all adults starting since November 2014. reported demographic, virological immunological variables at baseline assessed [on treatment (OT), modified ITT (mITT) those who reached 6 12 month follow-ups (M6 M12)....
To assess the clinical and immunovirological outcomes among naive patients with advanced HIV presentation starting an antiretroviral regimen in real-life settings.This was a multicentre, prospective cohort study. We included all treatment-naive adults disease (CD4+ T cell count < 200 cells/mm3or presence of AIDS-defining illness) who started therapy between 2010 2020. The main were mortality, virological effectiveness (percentage viral load ≤50 copies/mL) immune restoration CD4+ above 350...
Rapid initiation of ART after HIV diagnosis is recommended for individual and public health benefits. However, certain clinical ART-related considerations hinder immediate therapy.
Liver steatosis (LS) and liver fibrosis (LF) can increase the risk of cardiovascular disease in people with HIV, but their prevalence associated factors are poorly understood. This study aimed to assess LS LF a large cohort HIV.
Abstract Background While both the burden of therapy and individual drugs in bictegravir/tenofovir alafenamide/emtricitabine (BIC/TAF/FTC) dolutegravir/lamivudine differ, it is unclear whether their real-life tolerability may be also different. Methods Single-centre, clinical cohort analysis all virologically suppressed persons with HIV (PWH) who were first prescribed bictegravir as BIC/TAF/FTC or dolutegravir had taken ≥1 dose study medication. Major outcomes discontinuations either for any...
Objective: We analyzed the incidence rate of long-term events in patients on antiretroviral therapy (ART) previously exposed to interruption. Design: A single-center cohort study involving participants ART interruptions (ARTI) clinical trials ( n = 10) was conducted. Methods: Non-AIDS after resumption were analyzed. control group not ARTI randomly selected from same and a propensity score belonging estimated based age, sex, CD4 + nadir value, time HIV diagnosis ARTI, starting suppressed...
Abstract Purposes Since 2016, the World Health Organization has recommended universal antiretroviral therapy (ART) for all people living with Human Immunodeficiency Virus (PLHIV). This recommendation may have influenced characteristics and outcomes of PLHIV admitted to Intensive Care Unit (ICU). study aims identify changes in epidemiological clinical ICU, their short- medium-term before after implementation ART (periods 2006–2015 2016–2019). Methods retrospective, observational,...
Human immunodeficiency virus (HIV) infection is considered a chronic disease. Antiretroviral therapy has allowed persons with HIV (PLWHIV) to achieve the 90-90-90 objectives proposed by World Health Organization for 2020; but an additional challenge getting adequate health-related quality of life. A determining factor in life PLWHIV health care they perceive receive. In this sense, we aimed assess perception outpatient provided and identify possible areas improvement single-center,...
Decreasing medication burden with raltegravir plus lamivudine in virologically suppressed persons HIV (PWH) maintained efficacy and was well tolerated at 24 weeks, but more comprehensive data over longer follow-up are required.
BackgroundEpidemiological and immunovirological features of people living with HIV (PLWH) can vary by sex.AimTo investigate, particularly according to sex, characteristics PLWH who consulted a tertiary hospital in Barcelona, Spain, 1982-2020.MethodsPLWH, still active follow-up 2020 were retrospectively analysed age at diagnosis, data extraction (December 2020), birth place, CD4+ cell counts, virological failure.ResultsIn total, 5,377 (comprising 828 women; 15%) included. diagnoses women...
<h3>Background</h3> Magnetic resonance imaging (MRI) is the most sensitive modality for detection of sacroiliitis. Diagnosing sacroiliitis on MRI not always straightforward and can be challenging in some cases. <h3>Objectives</h3> To evaluate prevalence (according to ASAS criteria) other diagnoses sacroiliac MRI. analyse/compare these by sex, age service requesting study. <h3>Methods</h3> This a cross-sectional, multicentre, descriptive, retrospective study hospital and/or specialised care...
Abstract Background New regimens may provide better tolerability, convenience, and safety for nonoccupational human immunodeficiency virus (HIV) postexposure prophylaxis (PEP). For this reason, we evaluated the single-tablet regimen of doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF) 28 days. Methods This was a prospective, open-label, single-arm trial including individuals with potential HIV-1 exposure within 72 hours. The primary endpoint noncompletion PEP at day 28....